Ability of the combined clinical cell-cycle risk score to identify patients that benefit from multi versus single modality therapy in NCCN intermediate and high-risk prostate cancer Article

Web of Science: 000529525900385
International Collaboration

Cited authors

  • Tward, Jonathan David; Schlomm, Thorsten; Bardot, Stephen; Freedland, Stephen J.; Lenz, Lauren; Cohen, Todd; Stone, Steven; Bishoff, Jay

Publication date

  • 2020

Published in

International Standard Serial Number (ISSN)

  • 0732-183X


  • 38


  • 6